

Application Serial No.: 10/068,725
Amendment dated: February 27, 2006
Response to Office Action dated September 1, 2005

2

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method for inhibiting the proliferation of tumor cells comprising endogenous B-cell maturation antigen (BCMA) or transmembrane activator and calcium-modulator and cyclophilin ligand-interactor (TACI), comprising administering to the tumor cells a composition that comprises an antibody component, wherein the antibody component binds both BCMA and TACI, wherein the binding to TACI is at an epitope within a polypeptide consisting of ~~amino acid residues 105 to 166~~ at least one of amino acids 30 to 67 of SEQ ID NO: 4 and amino acids 68 to 154 of SEQ ID NO:4.

2. (Original) The method of claim 1, wherein the composition is administered to cells cultured *in vitro*.

3. (Original) The method of claim 1, wherein the composition is a pharmaceutical composition, and wherein the pharmaceutical composition is administered to a subject, which has a tumor.

4. (Original) The method of claim 1, wherein the composition comprises an anti-BCMA-TACI antibody component that is a naked BCMA-TACI antibody.

5. (Original) The method of claim 1, wherein the composition comprises an anti-BCMA-TACI antibody component that is a naked BCMA-TACI antibody fragment.

6. (Original) The method of claim 1, wherein the composition comprises an immunoconjugate that comprises an anti-BCMA-TACI antibody component and a therapeutic agent.

Application Serial No.: 10/068,725
Amendment dated: February 27, 2006
Response to Office Action dated September 1, 2005

3

7. (Original) The method of claim 6, wherein the therapeutic agent is selected from the group consisting of chemotherapeutic drug, cytotoxin, immunomodulator, chelator, boron compound, photoactive agent, photoactive dye, and radioisotope.

8. (Original) The method of claim 1, wherein the composition comprises an antibody fusion protein that comprises an anti-BCMA-TACI antibody component and a cytotoxic polypeptide.

9. (Cancelled)

10. (Currently amended) The method of claim 1, wherein the additional antibody component binds to an epitope within a polypeptide consisting of amino acid residues 110 to 118 of SEQ ID NO:4.

11. - 24. (Cancelled)

25. (New) The method of claim 1, further comprising administering a composition that comprises an additional antibody component, wherein the additional antibody component binds to an epitope within a polypeptide consisting of amino acid residues 105 to 166 of SEQ ID NO:4.

26. (New) The method of claim 1, wherein the binding to TACI is at an epitope within a polypeptide consisting of amino acids 30 to 67 of SEQ ID NO:4.

27. (New) The method of claim 1, wherein the binding to TACI is at an epitope within a polypeptide consisting of amino acids 68 to 154 of SEQ ID NO:4.

28. (New) The method of claim 1, wherein the binding to TACI is at an epitope within a polypeptide consisting of amino acids 39 to 50 of SEQ ID NO: 4.

29. (New) The method of claim 1, wherein the binding to TACI is at an epitope within a polypeptide consisting of amino acids 78 to 91 of SEQ ID NO:4.